Peter M Shaw

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi request reprint Generating and weighing evidence in drug development and regulatory decision making: 5th US FDA-DIA workshop on pharmacogenomics
    Peter M Shaw
    Merck and Co, Inc, Pharmacogenetics and Molecular Profiling, West Point, PA 19486, USA
    Pharmacogenomics 11:1629-35. 2010
  2. pmc EMT is the dominant program in human colon cancer
    Andre Loboda
    Merck, Sharp and Dohme, West Point, PA 19486, USA
    BMC Med Genomics 4:9. 2011

Collaborators

  • Issam Zineh
  • Andre Loboda
  • David B Jackson
  • Hongyue Dai
  • Pearl S Huang
  • Rob A E M Tollenaar
  • Michael V Nebozhyn
  • James W Watters
  • Deepak Agrawal
  • Laura van't Veer
  • Carolyne A Buser
  • Timothy J Yeatman

Detail Information

Publications2

  1. doi request reprint Generating and weighing evidence in drug development and regulatory decision making: 5th US FDA-DIA workshop on pharmacogenomics
    Peter M Shaw
    Merck and Co, Inc, Pharmacogenetics and Molecular Profiling, West Point, PA 19486, USA
    Pharmacogenomics 11:1629-35. 2010
    ..Furthermore, the complexities of conducting pharmacogenetic research in global drug-development programs was acknowledged as was the need for rigorous research designs and methodologies despite these challenges...
  2. pmc EMT is the dominant program in human colon cancer
    Andre Loboda
    Merck, Sharp and Dohme, West Point, PA 19486, USA
    BMC Med Genomics 4:9. 2011
    ..Colon cancer has been classically described by clinicopathologic features that permit the prediction of outcome only after surgical resection and staging...